Compare BDTX & SEVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDTX | SEVN |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 167.9M |
| IPO Year | 2020 | 2008 |
| Metric | BDTX | SEVN |
|---|---|---|
| Price | $1.84 | $6.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $10.00 | $9.55 |
| AVG Volume (30 Days) | ★ 558.5K | 162.4K |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 16.23% |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $29,383,000.00 |
| Revenue This Year | N/A | $18.67 |
| Revenue Next Year | N/A | $12.98 |
| P/E Ratio | ★ N/A | $36.39 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $6.74 |
| 52 Week High | $4.94 | $10.90 |
| Indicator | BDTX | SEVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 27.17 |
| Support Level | $1.76 | N/A |
| Resistance Level | $1.90 | $7.84 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 24.49 | 12.90 |
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.